Table 3 Association between genetic risk scores and longitudinal CSF biomarkers in PD patients and HCs.

From: Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease

  

p-tau/Aβ42

αSyn

Group

Predictors

β (SE)

P

β (SE)

P

PD

GRS-AD

4.25 (0.67)

<0.001

−0.18 (0.05)

0.001

GRS-PD

0.39 (0.62)

0.538

−0.07 (0.05)

0.137

time

0.28 (0.11)

0.008

−0.03 (0.01)

0.002

GRS-AD*GRS-PD

  

0.20 (0.07)

0.005

GRS-AD*time

0.27 (0.15)

0.082

0.04 (0.02)

0.008

GRS-PD*time

0.29 (0.13)

0.031

0.02 (0.01)

0.144

GRS-AD*GRS-PD*time

  

−0.05 (0.02)

0.021

Time-varying αSyn

0.65 (0.35)

0.062

  

Time-varying p-tau/Aβ42

  

0.01 (0.002)

0.010

HC

GRS-AD

8.53 (1.84)

<0.001

−0.10 (0.08)

0.226

GRS-PD

1.22 (2.08)

0.557

−0.01 (0.09)

0.886

time

0.42 (0.26)

0.103

0.01 (0.02)

0.615

GRS-AD*time

0.58 (0.34)

0.087

0.01 (0.02)

0.519

GRS-PD*time

0.14 (0.36)

0.710

−0.01 (0.02)

0.835

Time-varying αSyn

1.94 (0.72)

0.007

  

Time-varying p-tau/Aβ42

  

0.01 (0.002)

<0.001

  1. αSyn Alpha-synuclein, AD Alzheimer’s disease, GRS Genetic risk score, HC Healthy control, PD Parkinson’s disease, p-tau/Aβ42 Phosphorylated tau/42-residue amyloid-beta.
  2. Data are presented as the results of linear mixed models for each longitudinal CSF biomarker using GRS-AD, GRS-PD, time, GRS-AD*time, and GRS-PD*time as predictors. Significant interactions between the predictors were included as predictors. Covariates included age, sex, education, remaining CSF biomarker, and the first four principal components.
  3. Significant P values are indicated in bold.
Back to article page